louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06965218: Relation Between Aortic Sclerosis &Severity of Coronary Heart Disease.
Official title: Relation Between Aortic Valve Sclerosis and Severity of Coronary Heart Disease Assessed by Syntax Score in Sohag University Hospital
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Aortic Valve Sclerosis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2025-05-11
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 100a patients from both sex who are diagnosed to be aortic valve sclerosis and will undergo coronary angiography in Sohag university hospital

Brief summary: the goal of the study to identify the relation between aortic valve sclerosis and severity of coronary heart disease by performing transthoracic echo Doppler study for severity of aortic valve sclerosis in patient will undergo coronary angiography with calculation of syntax score as a tool for severity of coronary heart disease.


Eligibility criteria: Inclusion Criteria:

* Aortic sclerosis diagnosed by trans thoracic echo doppler

Exclusion Criteria:

* patients who known to be Rumatic heart disease or congenital aortic valve disease.

Primary outcomes:
measure: relation between Aortic valve sclerosis and severity of coronary heart disease
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag faculty of medicine
Study officials:
References:
Clinical trial NCT03317418: Can Pregnancy be Predicted According to ATR-FTIR Spectrophotometry of Incubation Medium of Embryos in IVF
Official title: Can Pregnancy be Predicted According to ATR-FTIR Spectrophotometry of Incubation Medium of Embryos in IVF
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2017-10-23
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women attending the fertility clinic at Hillel Yaffe Medical Center

Brief summary: The aim of this study is to examine the variability of culture media composition based on the ATR-FTIR (Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy) technique on the day of embryo transfer/vitrification. In addition, the study will explore whether variations detected in the culture medium can be linked to embryo quality and the chances of achieving pregnancy.


Eligibility criteria: Inclusion Criteria:

* Women undergoing IVF treatments with at least 4 embryos

Exclusion Criteria:

-

Primary outcomes:
measure: Spectrometry in embryo culture media
timeFrame: One year
measure: Embryo quality
timeFrame: One year
Secondary outcomes:
measure: Cycle outcomes
timeFrame: One year
Other outcomes:
Locations:
city: H̱adera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Einat Shalom Paz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01843218: Erectile Rating During the Treatment of Rectal Cancers Localized
Official title: Erectile Rating During the Treatment of Rectal Cancers Localized. Exploratory Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Rectal Cancer Stage I
Keywords: Localized rectal cancer in a male patient
Lead sponsor: Institut Bergonié
Sponsor class: OTHER
First posted: 2013-04-30
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Erectile dysfunction will be explored by recording R / P and self-administered questionnaire IIEF-5.

Detailed description: Erectile dysfunction will be explored by recording R / P and self-administered questionnaire IIEF-5. This dual evaluation will be made before the beginning of the therapeutic treatment and 3 months and 12 months after surgery. Assessed by IIEF-5 will be made only 6, 18 and 24 months after surgery. There will be no changes made to support oncology patients.

Eligibility criteria: Inclusion Criteria:

1. Male patient.
2. Age greater than 18 years.
3. Neoplastic rectal stage ≤ T3.
4. Patient sexually active before diagnosis.
5. Laparoscopic surgery.
6. Medico-surgical institute Bergonié.
7. Patient information and consent for participation in the study.

Exclusion Criteria:

1. Patients already treated for erectile dysfunction.
2. Absence of sexual activity before diagnosis.
3. Presence of secondary lesions at diagnosis (M +).
4. Classified T4 tumor preoperatively.
5. Surgery by laparotomy.
6. History of pelvic cancer surgery prostate or bladder.
7. History of pelvic radiotherapy (outside of the current process).
8. History of prostate or bladder neoplasia known.
9. Other neoplastic known.
10. Patient for psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study, patient deprived of liberty or under guardianship.

Primary outcomes:
measure: assess erectile dysfunction
timeFrame: 1 day
Secondary outcomes:
measure: Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer
timeFrame: 1 day
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Institut Bergonié
state: Aquitaine
Study officials:
affiliation: Institut Bergonié
name: EVRARD Serge, PU-PH
role: STUDY_CHAIR
References:
Clinical trial NCT03697018: Evaluation of Antagonist Wear Behavior and Patient Satisfaction of Zirconia Reinforced Lithium Silicate Glass When Compared to Monolithic Zirconia
Official title: Evaluation of Antagonist Wear Behavior and Patient Satisfaction of Monolithic Zirconia Versus Lithium Silicate Zirconia Crowns
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Wear of the Natural Enamel
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-10-05
Enrollment: 26
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: evaluation of wear behavior and patient satisfaction of monolithic zirconia and zirconia reinforced glass crowns after follow-up periods 0,3,6,12 months.

Detailed description: two groups of patients will be selected according to special inclusion criteria n=13 in each group total of 26. each group will receive one of the crowns used in this study either ( monolithic zirconia or zirconia reinforced lithium silicate glass) after crown delivery wear and patient satisfaction will be recorded at 0,3,6,12 moths follow-up periods.

Eligibility criteria: Inclusion Criteria:

1. Patient age range from 20-60 to be able to read and write in order to sign the informed consent document.
2. Patients physically and psychologically able to tolerate conventional restorative procedures.
3. Patients with no active periodontal and or pulpal diseases, having teeth with good restorations.
4. Patients with root canal treated teeth requiring full coverage restorations.
5. Patients indicated for full coverage (e.g. moderate to severe discoloration, coronal fracture, malposed or malformed teeth).
6. Patients willing to return for follow-up examinations and assessments

Exclusion Criteria:

1. Patients in the growth stage with partially erupted teeth.
2. Patient with poor oral hygiene.
3. Patients with psychiatric problems or unrealistic expectations
4. Patient with no opposite occluding dentition in the area intended for restoration.
5. Patient suffering from Para functional habits.

Primary outcomes:
measure: wear of the antagonist natural enamel
timeFrame: from baseline till one year
Secondary outcomes:
measure: patient satisfaction
timeFrame: from baseline till one year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02668718: Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer
Official title: Adjuvant Radiation Therapy vs. Watchful Waiting in Prostate Cancer Patients With Positive Margins or Capsular Penetration After Radical Prostatectomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Prostatic Neoplasms
Keywords: radiotherapy, adjuvant
prostatectomy
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2016-01-29
Enrollment: 250
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether adjuvant radiotherapy following radical prostatectomy in prostate cancer patients with positive margins or capsular penetration improves biochemical, overall and/or cancer specific survival and whether adjuvant radiotherapy is reasonably well tolerated when compared to watchful waiting.

Detailed description: In this study the investigators will evaluate adjuvant radiation therapy vs. watchful waiting in prostate cancer patients with positive margins or capsular penetration after radical prostatectomy. This is a randomized, open label, multicentre, collaborative study of FinnProstate Group and Finnish Radiation Oncology group.

Eligibility criteria: Inclusion Criteria:

Patients with pT3aN0M0 or pT2N0M0 prostate cancer with a positive margin, gleason score 2-10, preoperative PSA \< 20 ug/l, postoperative PSA \<0.5 ug/l after surgery (within 8 weeks), the WHO performance status 0-2, life expectancy at least 3 months, informed consent obtained.

Exclusion Criteria:

Other simultaneous cancer therapy including systemic endocrine therapy; more than 12 weeks has elapsed since surgery for prostate cancer; metastatic disease (N+ or M1); cancer invasion to the seminal vesicles; any other previous malignancy within the last 5 years except basalioma or squamous cell carcinoma of the skin; any contraindication to irradiation (severe locoregional infection, prior radiation therapy to the prostate/bladder); any physical or mental condition, which in the opinion of the investigator, may interfere with patient's ability to comply with scheduled visits.

Primary outcomes:
measure: Biochemical disease-free survival
timeFrame: Five years
measure: Overall survival
timeFrame: Five years
measure: Cancer specific survival
timeFrame: 5 years
Secondary outcomes:
measure: Local recurrence verified by needle or surgical biopsy
timeFrame: Five years
measure: Adverse events
timeFrame: Five years
Other outcomes:
Locations:
Study officials:
affiliation: Tampere University Hospital
name: Teuvo Tammela, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01784718: Buphenyl Therapy for Byler's Disease
Official title: Compassionate Use of Buphenyl® in the Treatment of Byler's Disease
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Byler Disease
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2013-02-06
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: This is a single patient compassionate use protocol to determine whether Buphenyl (4-phenylbutyrate) will improve the poor bile flow associated with Byler Disease.


Eligibility criteria: Inclusion Criteria:

* Byler Disease
* Cholestasis unresponsive to pharmacologic therapy

Exclusion Criteria:

* Allergy/Hypersensitivity to Buphenyl

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02872818: Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
Official title: The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Apoptotic Signal Pathways in Endometrial Hyperplasia
Keywords: Apoptotic signal pathway
Survivin
Bcl-2
Bax
c-Myc
Caspase-9
endometrial hyperplasia
endometrium cancer
Lead sponsor: Kayseri Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2016-08-19
Enrollment: 40
Sex: FEMALE
Minimum age (years): 8
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine apoptotic signaling pathways such as Survivin, Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial hyperplasia after metformin and medroxyprogesterone acetate administration.


Eligibility criteria: Inclusion criteria:

Forty-eight weeks old female Wistar-Albino rats, weighting between 180 and 260 g

Exclusion criteria.

We have no exclusion criteria because we examine drugs effects in the experimental rats

Primary outcomes:
measure: Survivin Gene Expression Levels in Rat Uterine Tissue
timeFrame: 4 months
measure: Bcl-2 Gene Expression Levels in Rat Uterine Tissue
timeFrame: 4 months
measure: Bax Gene Expression Levels in Rat Uterine Tissue
timeFrame: 4 months
measure: c-Myc Gene Expression Levels in Rat Uterine Tissue
timeFrame: 4 months
measure: Caspase-9 Expression Levels in Rat Uterine Tissue
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Kayseri Training and Research Hospital
Study officials:
affiliation: Kayseri Training and Research Hospital
name: Erdem SAHİN
role: STUDY_DIRECTOR
References:
Clinical trial NCT06906718: Evaluation of Long-term Visual Acuity Data After Bilateral Implantation of the Aspheric EDOF Lens ACUNEX® Vario
Official title: Evaluation of Long-term Visual Acuity Data After Bilateral Implantation of the Aspheric EDOF Lens ACUNEX® Vario (Model AN6V).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intraocular Lens
Lead sponsor: Teleon Surgical B.V.
Sponsor class: INDUSTRY
Collaborators: name: Charite University, Berlin, Germany
First posted: 2025-04-02
Enrollment: 8
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the ACUNEX® Vario study was to confirm long-term data on the visual quality and contrast sensitivity of an existing EDOF-IOL, which bears the CE mark and has been on the market since 2019.

Detailed description: The monocentric, retro-prospective, uncontrolled clinical study following Art. 82 MDR, §§ 47 MPDG and conducted according ISO 14155 shall confirm the long-term safety and performance of the AN6V - ACUNEX® Vario EDOF-IOL which has been marketed since 2019. This IOL model is designed to provide good distance and intermediate vision.

Eligibility criteria: Successful bilateral IOL implantation into the capsular bag with at least 12 months follow-up.

Primary outcomes:
measure: Visual Acuity
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité University Berlin
Study officials:
References:
Clinical trial NCT06061718: Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Official title: Multicenter, Open-label, Single-arm Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With Cataract Surgery
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Open Angle Glaucoma
Ocular Hypertension
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2023-09-29
Enrollment: 60
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.


Eligibility criteria: Inclusion Criteria:

* clinically significant age-related cataract eligible for phacoemulsification in the study eye
* open-angle glaucoma or ocular hypertension in the study eye
* successful, uncomplicated cataract surgery using small incision phacoemulsification cataract surgery and insertion of a foldable posterior chamber IOL

Exclusion Criteria:

* unmedicated (washed out) IOP of \>36 mmHg in the study eye
* hypersensitivity to travoprost or any other components of the travoprost intraocular implant
* vertical cup/disc ratio \> 0.8 in the study eye
* best spectacle corrected visual acuity of worse than 20/80 in the fellow eye
* any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Primary outcomes:
measure: Change from baseline in mean diurnal IOP
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Yerevan
country: Armenia
facility: Glaukos Clinical Study Site
Study officials:
affiliation: Glaukos Corporation
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05587218: Recognition of Second Language Spoken Words, Signs, and Characters Via Perception and Production in Adults
Official title: How Motor Cortex Supports L2 Acquisition of Spoken Words, Signs, and Characters Via Perception and Production
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Second Language Acquisition in Healthy Young Adults
Keywords: Second language
Word learning
Self-production
Lead sponsor: University of Alabama, Tuscaloosa
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2022-10-20
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Self-production facilitates acquisition of spoken words, signs, and characters from an unfamiliar second language. The proposed work investigates how motor cortex, a key part of the brain enabling body action, supports their acquisition via production as well as perception, providing insight into whether they are learned via mental simulation of the body actions used to produce them. It is hypothesized that activity in motor cortex will differ based on the body part used to produce lexical items (e.g., mouth vs. hands), will be greater for lexical items learned via production than observation, and will differentiate lexical items recognized successfully vs. unsuccessfully.


Eligibility criteria: Inclusion Criteria:

* Right-handed
* Native English speaker

Exclusion Criteria:

* Knowledge of sign language or languages with logographic characters
* Hearing or vision impairments
* Speech, language, or learning disorders
* Unsecured metal body implants

Primary outcomes:
measure: Functional activity in motor cortex location, 5 min, recognition
timeFrame: 5 minutes after learning
measure: Functional activity in motor cortex degree, 5 min, recognition
timeFrame: 5 minutes after learning
measure: Functional activity in motor cortex location, 1 week, recognition
timeFrame: 1 week after learning
measure: Functional activity in motor cortex degree, 1 week, recognition
timeFrame: 1 week after learning
Secondary outcomes:
Other outcomes:
Locations:
city: Tuscaloosa
country: United States
facility: University of Alabama, Tuscaloosa
state: Alabama
Study officials:
affiliation: University of Alabama, Tuscaloosa
name: Laura Morett, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02064218: Emerging Biomarkers in Hypertension
Official title: Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypertension
Lead sponsor: University of Pavia
Sponsor class: OTHER
Collaborators: name: Fondazione IRCCS Policlinico San Matteo di Pavia
First posted: 2014-02-17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with naive essential hypertension aged \< 65 years without previous cardiovascular events

Brief summary: First of all to evaluate the relationship between non-conventional biomarkers and essential hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood pressure control and non-conventional biomarkers in naive hypertensive patients


Eligibility criteria: Inclusion Criteria:

* essential hypertension
* naive to treatment
* \< 65 years

Exclusion Criteria:

* secondary hypertension
* previous cardiovascular events

Primary outcomes:
measure: Blood pressure reduction
timeFrame: 5 years
Secondary outcomes:
measure: Cardiovascular and metabolic biomarkers
timeFrame: 5 years
Other outcomes:
measure: Evaluation of vascular stiffness
timeFrame: 5 years
Locations:
city: Pavia
country: Italy
facility: IRCCS Policlinico S.Matteo Foundation
Study officials:
affiliation: University of Pavia
name: Giuseppe Derosa, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC Cardiovasc Disord. 2016 Apr 12;16:66. doi: 10.1186/s12872-016-0237-z.
citation: Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P. Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. Eur J Pharmacol. 2015 Nov 5;766:31-6. doi: 10.1016/j.ejphar.2015.09.030. Epub 2015 Sep 25.
citation: Derosa G, Mugellini A, Querci F, Franzetti I, Pesce RM, D'Angelo A, Maffioli P. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. Sci Rep. 2015 Aug 5;5:12603. doi: 10.1038/srep12603.
citation: Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P. A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. Cardiovasc Diabetol. 2015 Jul 30;14:95. doi: 10.1186/s12933-015-0254-8.
citation: Derosa G, Romano D, Bianchi L, D'Angelo A, Maffioli P. The effects of canrenone on inflammatory markers in patients with metabolic syndrome. Ann Med. 2015 Feb;47(1):47-52. doi: 10.3109/07853890.2014.969303. Epub 2014 Oct 16.